

For release: 5 March 2010

Medgenics, Inc.

('Medgenics' or the 'Company')

MEDGENICS SUCCESSFULLY CLOSES ADDITIONAL FINANCING ROUND

Medgenics (AIM: MEDG and MEDU), the company that is developing a novel approach to the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is pleased to announce that it has successfully closed an additional round of financing, raising gross proceeds of £726,168. Pursuant to a board resolution passed today, the Company has allotted and issued (credited as fully paid), conditional upon admission to trading on AIM:

- 14,273,000 new common shares of par value of US \$0.0001 each in the Company ("Common Shares") at a price of 5 pence per Common Share; and
- a further 192,591 Common Shares at a price of 6.5 pence per Common Share to certain of the directors and their related parties, as announced on 8 February 2010.

Application will be made by the Company for these Common Shares to be admitted to trading on AIM and dealings are expected to commence at 8am on 11 March 2010.

Following the admission to trading on AIM of these 14,465,591 new Common Shares, the total number of Common Shares in issue will be 137,914,618*. The resultant directors' interests* and significant shareholdings* will be as follows (excluding interests in warrants, options and debentures as previously announced):

Name	Number of Common Shares	% of Issued Share Capital*
The Executors of Lord Leonard Steinberg's estate	18,509,725	13.4%
Joel Kanter (director) including related interests	14,126,635	10.2%
CIBC Trust Company (Bahamas) Ltd. **	7,605,985	5.5%
Alta California Partners III L.P.	7,412,472	5.4%
Platinum Montaur Life Sciences I, LLC	7,190,208	5.2%
Vision Opportunity Master Fund Ltd.	7,094,851	5.1%
Koor Corporate Venture Capital, L.P.	5,393,821	3.9%
UK Private Healthcare Limited	5,000,000	3.6%
Chicago Investments Inc. **	4,400,807	3.2%
Andrew Pearlman (director)	1,235,019	0.9%
Eugene Bauer (director)	143,832	0.1%

The percentage of Common Shares not in public hands will be 25.9%*

Note

* Excluding any Common Shares issued pursuant to the block admission between 4 December 2009 and the date of this announcement.

** Included within the interests of Joel Kanter, a director of the Company

The directors believe that these additional funds will enable the Company to start the recruitment and treatment of further patients under its ongoing phase I/II anaemia trial and to further develop partnering initiatives in relation to its key current and proposed product candidates.

The Company now plans to use the proceeds from this successful fund raising to resume its current anaemia trial in higher dose groups, starting in the second quarter of 2010, using EPODURE Biopumps producing the therapeutic protein erythropoietin (EPO), which is the standard injected protein for treatment of anaemia with a US\$12bn value global market. This follows the recent announcement of the Company's first significant pre-clinical development and option agreement with a major international biopharmaceutical company to apply the Company's core Biopump tissue technology to treat a different major chronic disease, haemophilia, under which the Company has already received \$2.6million and expects to receive a further \$1.4million by the end of 2010. The Company also expects to receive a further \$1.3m of financial support during 2010 from the Israeli Office of the Chief Scientist and the directors are confident that these non-dilutive sources of finance will cover a significant portion of the Company's 2010 anticipated expenditure.

So far, seven patients have been treated in the phase I/II fixed-dose anaemia trial using a single administration of the EPODURE Biopumps. This single treatment is intended to replace months of frequent EPO injections now used in standard practice. To date six patients have received EPODURE Biopumps producing EPO at the lowest recommended dosage and one patient has received EPODURE Biopumps producing EPO at the next dosing level. EPO was successfully delivered by the treatment in all seven patients, with even the lowest dose causing the levels of haemoglobin in most patients to be sustained for months within the target range without any EPO injections. In one patient the haemoglobin level has been stabilised in the range for more than 16 months without requiring any of the weekly EPO injections he had received for more than a year prior to EPODURE treatment. Patients have found the treatment satisfactory and there have been no adverse events reported. The Company has now included some more detailed data on these trials on its website which can be found at www.medgenics.com.

In the continuation of this trial, additional patients will be treated using higher fixed dosage levels. This will be accomplished by administering more EPODURE Biopumps, titrated to deliver higher daily levels of EPO than with the first patients in the trial. This is designed to show dose response for EPODURE in a similar manner to that known for injected EPO, where higher doses result in statistically higher haemoglobin levels, even though dosage response and requirements vary from patient to patient. The treatment of additional patients in the trial is expected to provide substantially more data to further corroborate the strong results to date, and to show that this positive therapeutic effect will occur for 6 months or longer.

As this is an open trial, the Company anticipates that it will continue to provide updates as patients are treated and followed throughout 2010. The Company further anticipates additional licensing activity and new programs in the product pipeline during 2010.

Andrew Pearlman, CEO of Medgenics, commented:

"We have already reported that our tissue based Biopump technology produces and delivers therapeutic proteins continuously over many months and in a more natural manner than serial injections. This trial has shown exciting and unprecedented clinical results in treating anaemic patients with EPODURE Biopumps, which continuously produce EPO. We now aim to demonstrate that higher doses of EPODURE result in higher haemoglobin levels.

With these additional funds we can now proceed to recruit and treat patients at higher doses in this trial. This will also give us important information to help us develop ways to titrate the dose to meet individual needs of the patient in future clinical use.

Furthermore, the recent agreement with a major pharmaceutical company for haemophilia, as well as other active partnering interest, endorses the Board's view that the Company's Biopump has many potential commercially exploitable applications.

We believe that the Biopump, once fully developed, will represent the ultimate in personalised medicine, offering a new and cost effective way to both manufacture and deliver therapeutic proteins directly in the patient on an extended basis and thus provide a better and safer

protein therapy compared to serial injections and other alternatives and we look forward to updating the market with further positive news throughout 2010.”

For further information, please contact:

Andrew Pearlman CEO Medgenics, Inc	+ 972 4 902 8900
Mike Wort / Anna Dunphy De Facto Communications	+ 44 207 861 3838
James Pinner / Derek Crowhurst Blomfield Corporate Finance	+44 207 444 0800
Ian Callaway / Alex Matthey SVS Securities plc	+44 207 638 5600

Notes to Editors:

About Medgenics:

Medgenics is a clinical-stage biopharmaceutical Company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. Biopumps are made using needle biopsies taken from the lower layer of the patient’s skin under local anaesthetic, and processed during 10-14 days to become 30 mm long tissue biofactories producing the required protein. The requisite number of Biopumps are injected under the patient’s skin to provide sustained protein production and delivery for many months. The Company is developing the Biopump to provide substantially greater safety and reliability in protein treatment in a more cost effective manner than experienced with the existing injected protein therapies. Medgenics currently has three products in development based on this technology and addressing the indications of:

- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)
- Haemophilia - using a Biopump to produce clotting Factor VIII

The Company's Phase I/II clinical trial using EPODURE to treat anaemia in patients with chronic kidney disease, has demonstrated proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for six months or more, EPODURE Biopumps have already provided effective anaemia treatment in most of these patients for 6-12 months, even at the low administered dose.

Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies. In addition to treatments for Anaemia, Hepatitis-C, and Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US \$87 billion by 2010. Other potential applications of Biopumps producing various proteins include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity, and diabetes.